While Nexavant monotherapy showed strong tumor growth suppression compared with anti-PD-1 antibody monotherapy, the combination therapy did not exhibit better tumor growth suppression compared with the monotherapies (Figure 7F). The gene discussed is PDCD1; the disease is neoplasm.